Skip to main navigation Skip to search Skip to main content

A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin

  • Lai Wei
  • , Mingxiang Zhang
  • , Min Xu
  • , Wan Long Chuang
  • , Wei Lu
  • , Wen Xie
  • , Zhansheng Jia
  • , Guozhong Gong
  • , Yueqi Li
  • , Si Hyun Bae
  • , Yong Feng Yang
  • , Qing Xie
  • , Shumei Lin
  • , Xinyue Chen
  • , Junqi Niu
  • , Jidong Jia
  • , Tushar Garimella
  • , Anne Torbeyns
  • , Fiona McPhee
  • , Michelle Treitel
    • Philip D. Yin, Ling Mo
  • Peking University
  • The Sixth People's Hospital of Shenyang
  • Guangzhou No.8 People's Hospital
  • Kaohsiung Medical University
  • Tianjin Second People's Hospital
  • Capital Medical University
  • Tangdu Hospital, Fourth Military Medical University
  • Central South University
  • PLA No. 302 Hospital
  • Affiliated to Medical School of South East University
  • Shanghai Jiao Tong University
  • First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
  • Jilin University
  • Bristol-Myers Squibb

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science